



ForwardHealth **ALERT**
Wisconsin serving you

**TO**

All Providers, HMOs and Other Managed Care Programs

REGARDING

Coverage of Bivalent COVID-19 Vaccine Booster Doses for Members Aged 5 Through 11 Years and Changes to Coverage of Monovalent COVID-19 Vaccine Booster Doses

Coverage of Bivalent COVID-19 Vaccine Booster Doses for Members Aged 5 Through 11 Years and Changes to Coverage of Monovalent COVID-19 Vaccine Booster Doses

On October 12, 2022, the U.S. Food and Drug Administration (FDA) amended its emergency use authorizations of Moderna and Pfizer mRNA COVID-19 vaccines to authorize bivalent formulations as booster doses for individuals aged 5 through 11 years. As a result, the Pfizer monovalent mRNA COVID-19 vaccine is no longer authorized by the FDA as a booster dose for individuals aged 5 through 11 years. It is not covered by ForwardHealth for dates of service (DOS) on and after October 12, 2022. For DOS on and after October 12, 2022, ForwardHealth covers the following Current Procedural Terminology (CPT) codes for Moderna and Pfizer bivalent COVID-19 vaccines as booster doses for members aged 5 through 11 years.

PROCEDURE CODE FOR MODERNA BOOSTER DOSE (AGES 6-11 YEARS)	DESCRIPTION
91314	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use
0144A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose

PROCEDURE CODE FOR PFIZER BOOSTER DOSE (AGES 5-11 YEARS)	DESCRIPTION
91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
0154A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose

COVID-19-related ForwardHealth Alerts and Updates are available on the [COVID-19: ForwardHealth News and Resources](#) page of the Portal.